NCT06871007Enrolling by invitationPhase 1/2
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 11 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 21 Feb 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 1 Sept 2029
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Diseases
- Childhood cancers
- NCT number
- NCT06871007
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 22
- From 1 Sept 2024 to the primary completion date, 1 Sept 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \>18
- History of specific therapy for lymphomas.
- Drug intolerance
Who the study is looking for
- Age from 0 years to 17 years 11 months
- Established on the basis of histological and immunohistochemical studies, the diagnosis of PMLBL (the presence of programmed death-ligand on tumor cells is not necessary)
- Lack of specific therapy for lymphoma
- Signed informed consent
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dmitry Rogachev National Research Center Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
| Pavlov University, RM Gorbacheva Research Institute Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.